ANIP
ANI Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$71.20
−1.09%Aug 24, 2026, 00:00 UTC
Muthusamy "Samy" Shanmugam resigned as a director of ANI Pharmaceuticals, effective August 23, 2026.
Aug 24, 2026, 00:00 UTC
Henry Gosebruch was appointed as a director of ANI Pharmaceuticals, effective August 19, 2026, with an initial restricted stock award valued at $525,000.
Aug 20, 2026, 07:18 UTC
Aurora Investment Counsel acquired a new stake in ANI Pharmaceuticals, Inc., purchasing 26,890 shares valued at approximately $2,226,000, representing 0.12% ownership, as disclosed in a recent SEC filing.
Source:Aug 7, 2026, 10:50 UTC
ANI Pharmaceuticals reported second quarter 2026 financial results with net revenues of $266.0 million, up 25.9% year-over-year, and reaffirmed 2026 guidance for total net revenue of $1,080-$1,140 million and adjusted non-GAAP EBITDA of $285-$300 million.
Jul 16, 2026, 20:34 UTC
ANI Pharmaceuticals announces its intent to appeal the denial of its post-trial motions in the CG Oncology matter to the Delaware Supreme Court.
Source:Jul 13, 2026, 16:55 UTC
ANI Pharmaceuticals reported positive topline data from a Phase 4 trial of its fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis.
Source:Jun 10, 2026, 18:26 UTC
ANI Pharmaceuticals is expanding its product Cortrophin into the acute gout flares indication with a dedicated 90-person sales force.
Source: